SARS-CoV-2 disease (COVID-19) has dramatically increased since March 2020. There is insufficient data to establish the risk of acquiring the hyponatremia in patient with COVID-19 infection. We report here the clinical features and therapeutic course of the severe hyponatremia secondary to pituitary macroadenoma with confirmed COVID-19 pneumonia. This is a 59-year-old man without renal disease, who developed severe hyponatremia, hardly explained by the emetic episode and/or diuretic treatment with thiazides. We know that hyponatremia occurs in patients with hypopituitarism, but infrequently as first presenting feature of a pituitary tumor in the context of a respiratory infection by COVID-19, which has probably exacerbated its presentation. We conclude, that in our case, in addition to the finding of a non-functioning pituitary macroadenoma that determines a cortisol deficiency, we consider that COVID-19 infection could have played a role in the severity of the symptoms of hyponatremia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.